HIV/AIDS Treatment

Biopharm company announces start of clinical trial for HIV therapy

Published in Gene Therapy Weekly, October 7th, 2004

The Immune Response Corporation (IMNR), a biopharmaceutical company, announced the first patients have been enrolled at the Canadian site in its initial clinical trial investigating IR103, the company's newest product candidate in development for the treatment of HIV.

This trial, with active sites in the United Kingdom and Canada, will represent the first human experience with IR103, which combines the Company's patented HIV-1 Immunogen with Amplivax, an immunostimulatory oligonucleotide adjuvant.

The 2-part, 9-arm, randomized, single-blind, controlled, multi-center phase 1/2 study began this summer and will run for approximately 28 weeks with 80...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-10-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry